Research Article

You have full text access to this OnlineOpen article

Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: Continued observations

  1. Joel M. Kremer1,*,
  2. Michael E. Weinblatt2,
  3. Arthur D. Bankhurst3,
  4. Ken J. Bulpitt4,
  5. Roy M. Fleischmann5,
  6. Christopher G. Jackson6,
  7. Kelly M. Atkins7,
  8. Anyang Feng7,
  9. Daniel J. Burge7

Article first published online: 3 JUN 2003

DOI: 10.1002/art.11142

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 48, Issue 6, pages 1493–1499, June 2003

Additional Information

How to Cite

Kremer, J. M., Weinblatt, M. E., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Jackson, C. G., Atkins, K. M., Feng, A. and Burge, D. J. (2003), Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: Continued observations. Arthritis & Rheumatism, 48: 1493–1499. doi: 10.1002/art.11142

Author Information

  1. 1

    The Center for Rheumatology, Albany, New York

  2. 2

    Brigham and Women's Hospital, Boston, Massachusetts

  3. 3

    University of New Mexico School of Medicine, Albuquerque

  4. 4

    University of California at Los Angeles

  5. 5

    Metroplex Clinical Research Center, Dallas, Texas

  6. 6

    University of Utah Medical Center, Salt Lake City

  7. 7

    Immunex Corporation, Seattle, Washington

*The Center for Rheumatology, 1367 Washington Avenue, Suite 101, Albany, NY 12206

Publication History

  1. Issue published online: 3 JUN 2003
  2. Article first published online: 3 JUN 2003
  3. Manuscript Accepted: 19 FEB 2003
  4. Manuscript Received: 20 FEB 2002

Funded by

  • Immunex Corporation, Seattle, Washington

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (187K)

REFERENCES

  • 1
    Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, et al. Methotrexate in rheumatoid arthritis: a five-year prospective multicenter study. Arthritis Rheum 1994; 37: 1492–8.
    Direct Link:
  • 2
    Maetzel A, Bombardier C, Strand V, Tugwell P, Wells G. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey. J Rheumatol 1998; 25: 2331–8.
  • 3
    Furst DE, Kremer JM. Methotrexate in rheumatoid arthritis. Arthritis Rheum 1988; 31: 305–14.
    Direct Link:
  • 4
    Hoffmeister RT. Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med 1983; 75: 69–73.
  • 5
    Kremer JM. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years. Arthritis Rheum 1997; 40: 984–5.
    Direct Link:
  • 6
    Weinblatt M, Maier A, Fraser P, Coblyn JS. Long-term prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol 1998; 25: 238–42.
  • 7
    Pincus T, Marcum SB, Callahan LF. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second-line drugs and prednisone. J Rheumatol 1992; 19: 1885–94.
  • 8
    Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17: 994–1002.
  • 9
    Thompson PW, Kirwan JR, Barnes CG. Practical results of treatment with disease-modifying antirheumatoid drugs. Br J Rheumatol 1985; 24: 167–75.
  • 10
    Goodman TA, Polisson RP. Methotrexate: adverse reactions and major toxicities. Rheum Dis Clin North Am 1997; 20: 513–28.
  • 11
    Calabrese LH. Rheumatoid arthritis and primary care: the case for early diagnosis and treatment. J Am Osteopath Assoc 1999; 99: 313–21.
  • 12
    American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39: 713–22.
    Direct Link:
  • 13
    Bathon JM, Marin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–93.
  • 14
    Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999; 354: 1932–9.
  • 15
    Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159: 2542–50.
  • 16
    Fleischmann RM. Early diagnosis and treatment of rheumatoid arthritis for improved outcomes: focus on etanercept, a new biologic response modifier. Clin Ther 1999; 21: 1429–42.
  • 17
    Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27: 864–72.
    Direct Link:
  • 18
    Wolfe F. The natural history of rheumatoid arthritis. J Rheumatol 1996; 23: 13–22.
  • 19
    Wolfe F, Mitchell DM, Sibley J, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481–94.
    Direct Link:
  • 20
    Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986; 29: 706–14.
    Direct Link:
  • 21
    Weinblatt ME, Polisson R, Blotner SD, Sosman JL, Aliabadi P, Baker N, et al. The effects of drug therapy on radiographic progression of rheumatoid arthritis: results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum 1993; 36: 613–9.
    Direct Link:
  • 22
    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–9.
  • 23
    Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35: 498–502.
    Direct Link:
  • 24
    Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137–45.
    Direct Link:
  • 25
    Felson DT, Anderson JJ, Lange MLM, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures rather than twenty percent? Arthritis Rheum 1998; 41: 1564–70.
  • 26
    Kremer JM, Alarcón GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316–28.
    Direct Link:
  • 27
    Kremer JM, Lee RG, Tolman KG. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy: a prospective study with baseline and sequential biopsy samples. Arthritis Rheum 1989; 32: 121–7.
    Direct Link:
  • 28
    Kremer JM. Is methotrexate oncogenic in patients with rheumatoid arthritis? Semin Arthritis Rheum 1997; 26: 785–7.
  • 29
    Alarcón GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, et al. Risk factors associated with lung injury in methotrexate-treated rheumatoid arthritis patients: a multicenter, case-control study. Ann Intern Med 1997; 127: 356–64.
  • 30
    Schettler J, Wong J, Ramey D, Singh G. Prednisone use significantly increases the risk of hip fractures in rheumatoid arthritis [abstract]. Arthritis Rheum 1999; 42 Suppl 9: S136.
  • 31
    Chantry D. Tumour necrosis factor antagonists. Emerging Drugs 1999; 4: 5–13.
  • 32
    Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999; 57: 945–66.
  • 33
    Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28: 1238–44.
  • 34
    Klareskog L, Moreland LM, Cohen SB, Sanda M, Burge DJ. Global safety and efficacy of up to five years of etanercept (Enbrel) therapy [abstract]. Arthritis Rheum 2001; 44 Suppl 9:S77.
View Full Article (HTML) Get PDF (187K)